Lancet Oncol: Impact of neoadjuvant chemotherapy plus nintedanib on prognosis in patients with advanced muscle-invasive bladder cancer
Time of Update: 2022-05-21
For patients with muscle-invasive bladder cancer, the addition of nintedanib to the standard chemotherapy regimen is safe, but does not significantly improve the rate of pathological complete response .
The team of Xiao Gengfu / Zhang Leiping of our office and the team of Shen Jingshan / Xie Yuanchao of Shanghai Institute of Materia Medica, Chinese Academy of Sciences found that the anti-new
Time of Update: 2022-05-20
The study found that the oral nucleoside anti-new coronavirus drug VV116 has excellent antiviral effect on multiple sensitive cell lines of RSV.
The Balb/c mouse model was further used to explore the concentration of nucleoside metabolite X1 in the blood of mice after a single oral dose of VV116 25 mg/kg, 50 mg/kg and 100 mg/kg (Fig.
"The Lancet-Oncology": What about PD-(L)1 resistance in NSCLC patients
Time of Update: 2022-02-20
Previous studies have confirmed that the combination of PD(L)-1 inhibitors and CTLA-4 inhibitors shows synergy and has been used for first-line treatment of metastatic non-small cell lung cancer (NSCLC) .
Lancet Oncol: Anti-tumor activity of PARP inhibitor Talazoparib in advanced metastatic castration-resistant prostate cancer
Time of Update: 2021-08-14
PARP inhibitors have good anti-tumor activity in prostate cancer with metastatic castration resistance that directly or indirectly participates in homologous recombination repair (HRR) gene DNA damage response (DDR) mutations .
2021 BOC/BOA Professor Yuan Ying: Talking about the FIRE-4.5 study-new progress in the treatment of patients with BRAF V600E mutant mCRC
Time of Update: 2021-08-08
5 (AIO KRK-0116) study compared FOLFOXIRI (fluorouracil + leucovorin + oxaliplatin + irinotecan) in combination with cetuximab or benzalkonium in newly treated patients with BRAF V600E mutant mCRC Efficacy of Vallizumab .
The latest clinical data released by Eltanexor in the treatment of MDS refractory to demethylation drugs
Time of Update: 2021-06-16
In the 10 mg dose group (n=5), all patients had clinical benefit, 3 patients (60%) achieved complete bone marrow remission, and 2 patients (40%) had stable disease .
In the 20 mg dose group (n=10), 4 cases (40%) achieved complete bone marrow remission, and 3 cases (30%) had stable disease .
NEJM: Oral JAK inhibitor abroctinib for moderate to severe atopic dermatitis
Time of Update: 2021-03-26
Recently, researchers compared the JAK1 inhibitor Abroctinib with the interleukin-4 receptor monoclonal antibody Dupilumab for the treatment of atopic dermatitis.
Compared with placebo, abrocitinib can significantly improve the signs and symptoms of moderate to severe atopic dermatitis.
Dupixent's treatment of child-like dermatitis is approved by the European Union
Time of Update: 2021-03-05
At 16 weeks, patients in the treatment group who used 300 mg Dupixent (N=122) or 200 mg Dupixent (N=59) every two weeks experienced the following changes: to improve the extent and severity of the disease: .
3 minutes of instant noodles can't be digested for 32 hours
Time of Update: 2021-02-05
Gossip also claims that instant noodles difficult to digest because it is added a variety of antioxidants, additives, even bubble noodles bowls will release harmful substances, long-term consumption of harmful health.
Prevention of COVID-19 Lilly in the elderly and antibody effectiveness of up to 80
Time of Update: 2021-01-29
In this randomized, double-blind, placebo-controlled Phase 3 clinical trial, 965 subjects (299 nursing home residents and 666 staff) who tested negative for the new coronavirus at baseline were included in the evaluation and analysis of antibody prevention effectiveness.
Clin Cancer Research: Tazemetostat (EPZ-6438) Joint R-CHOP treatment of diffuse large B cell lymphoma
Time of Update: 2020-07-13
BACKGROUND: Histone methyl metastase EZH2 is the catalytic sub-base of the PRC2 complex involved in transcription regulation, with about 25% of patients with birth center B cells lymphoma carrying
Depatux-M combined temequinathemide therapy EGFR amplification relapse GBM
Time of Update: 2020-05-31
Backgrounded Depatux-M is a tumor-specific antibody drug coupling consisting of activated epithelial growth factor receptor (EGFR) antibodies (ABT-806) and toxin monomethylauristatin-F Martin van den
1 case of hypertrophy hard meningitis with a recurrence of headache after treatment
Time of Update: 2020-05-29
Hypertrophic hard meningitis (hypertrophiciciccial pachyhys, HCP) is a rare inflammatory hypertrophic disease characterized by epidural limitation or diffuse thickening, fibrosis as the main charac